c MRX-I is a potent oxazolidinone antibiotic against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), penicillin-intermediate S. pneumoniae (PISP), and vancomycin-resistant enterococci (VRE). In this study, the in vivo efficacy of orally administered MRX-I was evaluated using linezolid as a comparator. MRX-I showed the same or better efficacy than linezolid in both systemic and local infection models against the tested strains.
In Vivo Antibacterial Activity of MRX-I, a New Oxazolidinone
. MRX-I demonstrated comparable or slightly higher activity than linezolid and was active against enterococci resistant to both vancomycin and teicoplanin. In addition, MRX-I exhibited bactericidal activities against staphylococci and streptococci but was bacteriostatic against enterococci (D.-M. Zhu, Y.-Y. Zhang, and W. Wang, unpublished data). In this study, the potent in vitro activities of MRX-I against staphylococci, streptococci, and enterococci were confirmed in our laboratory. Next, the in vivo efficacy of MRX-I was evaluated in mouse systemic and local infection models, using linezolid as the reference agent, as it is the only commercially available oxazolidinone. All in vivo experiment procedures were approved by the Animal Research Committee of the Institute of Medicinal Biotechnology.
MIC and MBC determinations. MIC and minimal bactericidal concentration (MBC) determinations were conducted by the agar dilution method and broth macrodilution method, respectively, according to CLSI/NCCLS recommendations (1, 2), using linezolid, vancomycin, and teicoplanin as the reference agents. The test isolates included methicillin-susceptible staphylococci (methicillin-susceptible S. aureus [MSSA] and methicillin-susceptible S. epidermidis [MSSE] ), methicillin-resistant staphylococci (MRSA and MRSE), penicillin-susceptible S. pneumoniae (PSSP), penicillin-intermediate S. pneumoniae (PISP), penicillinresistant S. pneumoniae (PRSP), vancomycin-susceptible enterococci (VSE), vancomycin-resistant enterococci (VRE), and Streptococcus pyogenes. As shown in Table 1 , MRX-I demonstrated potent activities against staphylococci, streptococci, and enterococci, including antibiotic-resistant isolates such as MRSA, MRSE, PISP, PRSP, and VRE. The activity of MRX-I was similar to (for S. aureus, S. pneumoniae, S. pyogenes, Enterococcus faecalis, and Enterococcus faecium) or slightly higher than (for S. epidermidis) that of linezolid. MRX-I was bacteriostatic against enterococci (MBC/MICs, Ͼ32 g/ml for most of the isolates) but showed very weak bactericidal activities against staphylococci (MBC/MIC range, 8 to 32 g/ml for most of the isolates) and some streptococci (MBC/MIC, 8 g/ml for 4 out of 14 isolates), as well as relatively high bactericidal activities against 10 out of 14 streptococcal isolates (MBC/MICs, 2 to 4 g/ml).
Mouse systemic infection model. The in vivo therapeutic efficacies of MRX-I and the comparator linezolid in the mouse systemic infection model were assessed with 5 strains of S. aureus, 3 strains of S. pneumoniae, 3 strains of E. faecalis, and 1 strain of S. pyogenes ( Table 2 ). The experiment was carried out by a method adapted from the literature (3). For each isolate infection, 110 CD-1 ICR mice (body weight, 18 to 22 g) were allocated randomly into 11 groups with 5 regimens for each compound and 1 control group (10 mice per group, 5 males and 5 females). The mice were infected intraperitoneally with 0.5 ml of a bacterial suspension in 5% mucin (100% minimum lethal dose). At 1 h and 5 h postinfection, 5 dose levels of each compound were administered orally. were evaluated with CD-1 ICR mice (body weight, 23 to 27 g; 10 mice per group, half males, half females) by previously published methods, with modifications (5, 6). The mice were immunocompromised using cyclophosphamide (150 mg/kg of body weight/ day for 3 days) (7) prior to infection by right thigh intramuscular injection of 0.1 ml bacterial suspension in saline (challenge dose, 4.2 ϫ 10 5 CFU/mouse for S. aureus ATCC 29213, 4.6 ϫ 10 4 CFU/ mouse for S. aureus 0605). Five different doses (5.0, 10.0, 20.0, 40.0, and 80.0 mg/kg) of MRX-I and the reference compound linezolid were orally administered twice, at 2 h and 6 h after infection, respectively. The mice were sacrificed at 24 h postinfection, and the right thigh muscles were removed aseptically. The muscles were weighed and homogenized in saline (0.1 g tissue to 1 ml final volume), and the viable colony counts were determined by spreading 0.1 ml properly diluted homogenates onto nutrient agar plates and incubating them at 35°C for 48 h. The log 10 CFU/g thigh was calculated thereafter, and the statistical significance was determined by SPSS 13.0. The lower detection limit was 2 log 10 CFU/g, which corresponded to the lowest dilution of muscle tissue of 10 Ϫ1 that avoided significant drug carryover. The results are shown in Table 3 . MRX-I and linezolid exhibited dose-dependent efficacy in mouse thigh infections by S. aureus isolates used in the study, with thigh colony counts that were significantly lower (P Ͻ 0.01) than those of the corresponding controls for most of the tested doses. Challenging the neutropenic mice with 4. In conclusion, the in vitro activity of MRX-I was confirmed by MIC and MBC determinations, and the in vivo therapeutic efficacies of MRX-I were evaluated using animal models of mouse systemic and mouse neutropenic thigh infections. The MIC results (Table 1 ) demonstrated that MRX-I had activity that was comparable to or slightly higher than that of linezolid and was active against antibiotic-resistant isolates such as MRSA, MRSE, PISP, PRSP, and VRE. MBC determinations (Table 1) indicated that MRX-I was a bacteriostatic agent against enterococci but a very weak bactericidal agent against staphylococci and some streptococci (4 out of 14 isolates), as well as a relatively strong bactericidal agent against most streptococci (10 out of 14 isolates).
The results from mouse systemic infections (Table 2) 
